Michael M. Boyiadzis

Hematology
200 Meyran Ave Ste 318
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica
Published: March 20, 2026

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

Journal: JCO clinical cancer informatics
Published: December 02, 2025

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Journal: Cancer
Published: March 25, 2025

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.

Journal: Haematologica
Published: February 18, 2024

Blast-Derived Small Extracellular Vesicles in the Plasma of Patients with Acute Myeloid Leukemia Predict Responses to Chemotherapy.

Blast-Derived Small Extracellular Vesicles in the Plasma of Patients with Acute Myeloid Leukemia Predict Responses to Chemotherapy.

Journal: Biomedicines
Published: November 06, 2023

Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.

Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.

Journal: American journal of hematology
Published: August 24, 2023

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

Journal: Blood advances
Published: April 26, 2023

Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.

Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.

Journal: Leukemia
Published: March 23, 2023

Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.

Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.

Journal: Leukemia & lymphoma
Published: February 01, 2023

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

Journal: Cancer
Published: October 21, 2022

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.

Journal: Leukemia & lymphoma
Published: September 08, 2022

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

Journal: Blood advances
Published: July 22, 2022
Showing 1-12 of 83

Last Updated: 09/26/2026